Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 761571, 7 pages
http://dx.doi.org/10.4061/2010/761571
Research Article

Combined Analysis of CSF Tau, A 42, A 1–42% and A 1– % in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

1Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Henricistrasse 92, 45136 Essen, Germany
2Department of Psychiatry, Psychotherapy, Rheinische Kliniken Essen, University of Duisburg-Essen, 45147 Essen, Germany
3Department of Psychiatry and Psychotherapy, University of Erlangen, Schwabachanlage 6, 91054 Erlangen, Germany
4Paracelsus-Elena Klinik, University of Goettingen, 34128 Kassel, Germany
5Institute for Neurology, University of Ulm, 89075 Ulm, Germany

Received 15 April 2010; Revised 8 July 2010; Accepted 11 July 2010

Academic Editor: Lucilla Parnetti

Copyright © 2010 Mirko Bibl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Dubois, H. H. Feldman, C. Jacova et al., “Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria,” The Lancet Neurology, vol. 6, no. 8, pp. 734–746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Otto, P. Lewczuk, and J. Wiltfang, “Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases,” Methods, vol. 44, no. 4, pp. 289–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Bibl, B. Mollenhauer, P. Lewczuk et al., “Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias,” Molecular Psychiatry, vol. 12, no. 7, pp. 671–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Bibl, B. Mollenhauer, H. Esselmann et al., “CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia,” Brain, vol. 129, no. 5, pp. 1177–1187, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. World Medical Organisation, “Declaration of Helsinki,” British Medical Journal, vol. 313, pp. 1448–1449, 1996. View at Google Scholar
  6. G. McKhann, D. Drachman, and M. Folstein, “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Google Scholar
  7. I. G. McKeith, D. W. Dickson, J. Lowe et al., “Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium,” Neurology, vol. 65, no. 12, pp. 1863–1872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. W. R. G. Gibb and A. J. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 51, no. 6, pp. 745–752, 1988. View at Google Scholar · View at Scopus
  9. F. Hulstaert, K. Blennow, A. Ivanoiu et al., “Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF,” Neurology, vol. 52, no. 8, pp. 1555–1562, 1999. View at Google Scholar · View at Scopus
  10. J. Wiltfang, H. Esselmann, M. Bibl et al., “Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation,” Journal of Neurochemistry, vol. 81, no. 3, pp. 481–496, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Bibl, H. Esselmann, M. Otto et al., “Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid β peptides,” Electrophoresis, vol. 25, no. 17, pp. 2912–2918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. W. J. Youden, “Index for rating diagnostic tests,” Cancer, vol. 3, no. 1, pp. 32–35, 1950. View at Google Scholar · View at Scopus
  13. K. Blennow, “Cerebrospinal fluid protein biomarkers for Alzheimer's disease,” NeuroRx, vol. 1, no. 2, pp. 213–225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Kanemaru, N. Kameda, and H. Yamanouchi, “Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies,” Neurology, vol. 54, no. 9, pp. 1875–1876, 2000. View at Google Scholar · View at Scopus
  15. E. Gómez-Tortosa, I. Gonzalo, S. Fanjul et al., “Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease,” Archives of Neurology, vol. 60, no. 9, pp. 1218–1222, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Mollenhauer, L. Cepek, M. Bibl et al., “Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies,” Dementia and Geriatric Cognitive Disorders, vol. 19, no. 2-3, pp. 164–170, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bibl, B. Mollenhauer, H. Esselmann et al., “CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies,” Journal of Neural Transmission, vol. 113, no. 11, pp. 1771–1778, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. E. Jansen, I. Vermes, and R. A. I. de Vos, “Cerebrospinal-fluid τ protein and aspartate aminotransferase in Parkinson's disease,” The Lancet, vol. 351, no. 9109, pp. 1105–1106, 1998. View at Google Scholar · View at Scopus
  19. B. Mollenhauer, C. Trenkwalder, N. von Ahsen et al., “Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia,” Dementia and Geriatric Cognitive Disorders, vol. 22, no. 3, pp. 200–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Hesse, L. Rosengren, N. Andreasen et al., “Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke,” Neuroscience Letters, vol. 297, no. 3, pp. 187–190, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Bibl, B. Mollenhauer, H. Esselmann et al., “Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review,” Dementia and Geriatric Cognitive Disorders, vol. 25, no. 3, pp. 256–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Davies, J. Resnick, B. Resnick et al., “Consensus report of the working group on: “molecular and biochemical markers of Alzheimer's disease”,” Neurobiology of Aging, vol. 19, no. 2, pp. 109–116, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Lewczuk and J. Wiltfang, “Neurochemical dementia diagnostics: state of the art and research perspectives,” Proteomics, vol. 8, no. 6, pp. 1292–1301, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Shoji and M. Kanai, “Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness,” Journal of Alzheimer's Disease, vol. 3, no. 3, pp. 313–321, 2001. View at Google Scholar · View at Scopus
  25. P. Lewczuk, G. Beck, H. Esselmann et al., “Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides,” Clinical Chemistry, vol. 52, no. 2, pp. 332–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Wiltfang, H. Esselmann, M. Bibl et al., “Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load,” Journal of Neurochemistry, vol. 101, no. 4, pp. 1053–1059, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Mollenhauer, H. Esselmann, C. Trenkwalder et al., “CSF amyloid-ß peptides in neuropathologically diagnosed dementias with Lewy bodies and Alzheimer's type,” Brain, vol. 129, no. 5, pp. 1177–1187, 2006. View at Google Scholar
  28. B. Mollenhauer, V. Cullen, I. Kahn et al., “Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration,” Experimental Neurology, vol. 213, no. 2, pp. 315–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Jesse, P. Steinacker, S. Lehnert, F. Gillardon, B. Hengerer, and M. Otto, “Neurochemical approaches in the laboratory diagnosis of parkinson and parkinson dementia syndromes: a review,” CNS Neuroscience and Therapeutics, vol. 15, no. 2, pp. 157–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Bibl and J. Wiltfang, “Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics,” Expert Review of Proteomics, vol. 5, no. 2, pp. 153–156, 2008. View at Publisher · View at Google Scholar · View at Scopus